FibroBiologics, Inc.
FBLG
$0.26
-$0.02-5.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.24M | 9.81M | 9.70M | 9.50M | 9.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.65M | 17.77M | 16.09M | 14.82M | 13.74M |
| Operating Income | -16.65M | -17.77M | -16.09M | -14.82M | -13.74M |
| Income Before Tax | -18.65M | -18.50M | -13.22M | -7.67M | -11.16M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.65 | -18.50 | -13.22 | -7.67 | -11.16 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.65M | -18.50M | -13.22M | -7.67M | -11.16M |
| EBIT | -16.65M | -17.77M | -16.09M | -14.82M | -13.74M |
| EBITDA | -16.41M | -17.55M | -15.89M | -14.64M | -13.58M |
| EPS Basic | -0.44 | -0.48 | -0.36 | -0.21 | -0.35 |
| Normalized Basic EPS | -0.28 | -0.30 | -0.23 | -0.13 | -0.22 |
| EPS Diluted | -0.44 | -0.48 | -0.36 | -0.21 | -0.35 |
| Normalized Diluted EPS | -0.28 | -0.30 | -0.23 | -0.13 | -0.22 |
| Average Basic Shares Outstanding | 178.56M | 152.51M | 142.95M | 137.04M | 131.50M |
| Average Diluted Shares Outstanding | 178.56M | 152.51M | 142.95M | 137.04M | 131.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |